Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders
Shots:
- StrideBio to receive $30M upfront & near term pre-clinical milestones- $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed
- StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three targets including Friedreich’s Ataxia (FA)
- StrideBio’s gene therapy technology is used to develop adeno-associated viral (AAV) therapies for rare diseases able to evade pre-existing antibodies. In 2018- Takeda Ventures funded Stride Bio for the development of AAV technology
Ref: Mitsubishi Tanabe Pharma | Image:Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
